drug approval process – The Milli Chronicle

Tuesday, November 4, 2025

Latest:

Saudi Arabia Strengthens Public Safety with Nationwide Early Warning System Tests
Jeddah’s Cultural Renaissance Captivates Global Audience at London’s World Travel Market
Saudi Students Gain Hands-On Experience in Restoring Historic Mosques Through National Heritage Program
Saudi Foreign Minister Joins Regional Leaders in Istanbul Talks to Advance Peace Efforts in Gaza
Saudi Forum Champions “Sufficiency Before Efficiency” at UN Climate Conference in Brazil

Factual Version of a Story

Featured News World

NewsDesk Milli Chronicle November 4, 2025 Center for Drug Evaluation and Research, clinical trials, drug approval process, drug safety, ethical governance, FDA ethics, FDA leadership change, FDA modernization, FDA reform, Food and Drug Administration, global drug safety, health policy, healthcare transparency, medical innovation, medical research, pharmaceutical innovation, pharmaceutical regulation, public health, Robert F. Kennedy Jr., U.S. health agencies, US FDA

US FDA’s Drug Division Undergoes Leadership Transition to Strengthen Integrity and Innovation

The U.S. Food and Drug Administration begins a new chapter in its drug evaluation and research division, focusing on ethics,

Featured Health Lifestyle

NewsDesk Milli Chronicle October 9, 2025October 9, 2025 $5.2 billion deal, Akero Therapeutics, Akero Therapeutics stock, and future of liver disease treatment., biopharma deal 2025, biotech acquisition, biotech investment, biotech partnership, biotechnology news 2025, cardiometabolic health, clinical trial success, Denmark pharmaceutical industry, drug approval process, drug pipeline expansion, Efruxifermin, efruxifermin clinical trials, Eli Lilly competition, GLP-1 drug development, healthcare innovation, healthcare investment news, late-stage drug trials, liver disease drug, liver disease research, liver scarring reversal, MASH drug approval, MASH treatment, metabolic disease therapy, metabolic dysfunction-associated steatohepatitis, Mike Doustdar, Novo Nordisk, Novo Nordisk acquisition, Novo Nordisk CEO, Novo Nordisk global expansion, Novo Nordisk growth strategy, Novo Nordisk strategic acquisition, obesity and diabetes drugs, pharma R&D deal, pharmaceutical industry update, pharmaceutical innovation, pharmaceutical merger, pharmaceutical research and development, Wegovy manufacturer

Novo Nordisk Makes Bold $5.2 Billion Move with Akero Buyout to Accelerate Liver Disease Breakthroughs

In a landmark deal marking a new era under CEO Mike Doustdar, Novo Nordisk acquires Akero Therapeutics for up to